Impact of Bevacizumab on Survival in Glioblastoma Patients
Author Information
Author(s): Laviv Yosef, Regev Ohad, Kanner Andrew A., Fichman Susana, Limon Dror, Siegal Tali, Yust-Katz Shlomit, Benouaich-Amiel Alexandra
Primary Institution: Beilinson Hospital, Rabin Medical Center
Hypothesis
This study aims to evaluate the potential impact of second-line bevacizumab treatment on survival in patients with subventricular zone glioblastoma.
Conclusion
Bevacizumab as a second-line therapy may positively affect survival after relapse in subventricular zone glioblastoma patients.
Supporting Evidence
- Bevacizumab treatment significantly prolonged survival time from first relapse by an average of more than 4 months.
- The only statistically significant difference between groups was the rate of re-surgery, which was higher in the non-bevacizumab group.
- Patients treated with both re-surgery and bevacizumab had the longest mean overall survival of the entire cohort.
Takeaway
This study found that a medicine called bevacizumab can help people with a type of brain cancer live longer after their first treatment doesn't work anymore.
Methodology
The study reviewed medical records of adult patients with newly diagnosed subventricular zone glioblastoma treated between 2011 and 2021, comparing those treated with bevacizumab after first relapse to those who were not.
Potential Biases
Potential biases due to the retrospective nature of the study and the inability to account for all treatment variations.
Limitations
The study's retrospective design may introduce biases, and the small cohort size limited some statistical analyses.
Participant Demographics
The cohort included 34 men and 33 women with a mean age of 58.11 years.
Statistical Information
P-Value
0.028
Confidence Interval
95% CI 0.34–0.94
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website